Algeta ASA has announced the election of Hilde Furberg, a senior vice president for rare disease at Genzyme (Sanofi), as one of two new non-executive directors of the company. Mrs Furberg has worked for 30 years in the pharmaceutical industry with several posts at Genzyme and prior to that, at Baxter International Inc. She holds a master of science degree in nuclear analytical chemistry from the University of Oslo. The second new director, Paolo Pucci, is chief executive and a member of the board of ArQule Inc, a US-based cancer therapeutics company. Mr Pucci was formerly president in charge of the Bayer-Schering Pharmaceuticals global oncology and specialised therapeutics business units. He holds an MBA from the University of Chicago and is a graduate of the Universita Degli Studi Di Napoli in Italy.
Algeta announced the appointments on 12 April.
Copyright 2013 Evernow Publishing Ltd